Prestige Consumer misses Q1 revenue estimates, to acquire Pillar5 Pharma
Overview
Prestige Consumer's Q1 rev drops to $249.5 mln, missing analysts' expectations
Diluted EPS for fiscal Q1 rises 6% yr/yr to $0.95
Co to acquire Pillar5 Pharma, addressing eye care supply chain issues
Outlook
Prestige lowers fiscal 2026 revenue outlook to $1,100 to $1,115 mln
Company now anticipates fiscal 2026 EPS of $4.50 to $4.58
Prestige expects eye care supply improvements in second half of fiscal 2026
Company maintains fiscal 2026 free cash flow forecast of $245 mln or more
Result Drivers
SUPPLY CONSTRAINTS - Revenue decline attributed to limited ability to supply of Clear Eyes products
INTERNATIONAL GROWTH - Strong growth in international OTC segment partially offset revenue decline
ACQUISITION STRATEGY - Acquisition of Pillar5 Pharma aimed at improving eye care supply chain
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Miss | $249.53 mln | $261 mln (6 Analysts) |
Q1 Net Income |
| $47.47 mln |
|
Q1 Gross Profit |
| $140.33 mln |
|
Q1 Operating Expenses |
| $68.58 mln |
|
Q1 Operating Income |
| $71.76 mln |
|
Q1 Pretax Profit |
| $61.78 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc is $90.00, about 16.5% above its August 6 closing price of $75.16
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago
Press Release: ID:nGNX95r4hg
